Holly Prigerson on Chemotherapy Regimens for Patients With Advanced Gastric Cancer

Holly G. Prigerson, PhD
Published: Thursday, Jan 21, 2016



Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

For metastatic, late-stage patients with a performance status between 1 and 2, it is questionable whether chemotherapy would be beneficial, in terms of quality of life, in the third-line setting, Prigerson explains. In a study, patients with a good performance status who were on chemotherapy were found to have a worse quality of death compared with those who did not receive chemotherapy (70%). 

For those with a poor performance status, there was little harm or benefit, she adds. 

<<< View more from the 2016 GI Cancer Symposium



Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

For metastatic, late-stage patients with a performance status between 1 and 2, it is questionable whether chemotherapy would be beneficial, in terms of quality of life, in the third-line setting, Prigerson explains. In a study, patients with a good performance status who were on chemotherapy were found to have a worse quality of death compared with those who did not receive chemotherapy (70%). 

For those with a poor performance status, there was little harm or benefit, she adds. 

<<< View more from the 2016 GI Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x